Final results from a phase i clinical trial evaluating the safety, immunogenicity, and anti-tumor activity of SNS-301 in men with biochemically relapsed prostate cancer

Journal article

Peer reviewed

L. T. Nordquist, H. Ghanbari, J. J. Elist, J. C. Oliver, W. Gannon, A. Shahlaee, S. Fuller and N. Shore

Annals of oncology, Vol.29, pp.viii136-viii136

10/01/2018

PMID: 32136207

Files and links (1)

url

https://doi.org/10.1093/annonc/mdy279.404View

Published (Version of record) Open

1 Record Views

Title: Final results from a phase i clinical trial evaluating the safety, immunogenicity, and anti-tumor activity of SNS-301 in men with biochemically relapsed prostate cancer
Creators: L. T. Nordquist - Urology Cancer Center and GU Research Network
H. Ghanbari - Sensei Biotherapeutics (United States)
J. J. Elist - Private Medical Practice, CA, United States
J. C. Oliver - Accelovance (United States)
W. Gannon - Capital University
A. Shahlaee - Sensei Biotherapeutics (United States)
S. Fuller - Sensei Biotherapeutics (United States)
N. Shore - Carolina Urologic Research Center
Publication Details: Annals of oncology, Vol.29, pp.viii136-viii136
Identifiers: 991006262525402656
Academic Unit: Radiology
Language: English
Resource Type: Journal article